tiprankstipranks
Trending News
More News >
Resmed (RMD)
NYSE:RMD
US Market

Resmed (RMD) Stock Forecast & Price Target

Compare
1,091 Followers
See the Price Targets and Ratings of:

RMD Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
9 Buy
6 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$265.11
▲(7.31%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $265.11 with a high forecast of $290.00 and a low forecast of $240.00. The average price target represents a 7.31% change from the last price of $247.05.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"171":"$171","201":"$201","231":"$231","261":"$261","291":"$291"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$290.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":265.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$265.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$240.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[171,201,231,261,291],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,235.98,240.1353846153846,244.29076923076923,248.44615384615383,252.60153846153844,256.75692307692304,260.9123076923077,265.0676923076923,269.2230769230769,273.3784615384615,277.5338461538461,281.6892307692308,285.8446153846154,{"y":290,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,235.98,238.22076923076924,240.46153846153845,242.7023076923077,244.94307692307692,247.18384615384616,249.42461538461538,251.66538461538462,253.90615384615384,256.1469230769231,258.3876923076923,260.6284615384615,262.8692307692308,{"y":265.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,235.98,236.28923076923076,236.59846153846152,236.9076923076923,237.21692307692308,237.52615384615385,237.8353846153846,238.14461538461538,238.45384615384614,238.7630769230769,239.0723076923077,239.38153846153847,239.69076923076923,{"y":240,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":172.67,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.21,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.49,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.19,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$290.00Average Price Target$265.11Lowest Price Target$240.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on RMD
David BaileyMorgan Stanley
Morgan Stanley
$280$286
Buy
15.77%
Upside
Reiterated
05/20/25
Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities
Bank of America Securities Analyst forecast on RMD
Lyanne HarrisonBank of America Securities
Bank of America Securities
$280
Buy
13.34%
Upside
Reiterated
05/20/25
Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109's Appeal
UBS
$285
Buy
15.36%
Upside
Reiterated
05/20/25
UBS reiterates Buy Rating on ResMed (RMD)UBS analyst Marcus Curley reiterated a Buy rating and $285.00 price target on ResMed (NYSE: RMD).
Needham
Hold
Reiterated
05/20/25
Resmed (RMD) Receives a Hold from Needham
Jefferies Analyst forecast on RMD
Unknown AnalystJefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on RMD.
RBC Capital Analyst forecast on RMD
Craig Wong-PanRBC Capital
RBC Capital
$247$255
Hold
3.22%
Upside
Reiterated
04/25/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Resmed (NYSE: RMD) and Thermo Fisher (NYSE: TMO)
Piper Sandler Analyst forecast on RMD
Adam MaederPiper Sandler
Piper Sandler
$260$248
Hold
0.38%
Upside
Reiterated
04/24/25
Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)
Oppenheimer Analyst forecast on RMD
Suraj KaliaOppenheimer
Oppenheimer
Hold
Reiterated
04/24/25
Oppenheimer reiterates Perform Rating on ResMed (RMD)Oppenheimer analyst Suraj Kalia reiterated a Perform rating on ResMed (NYSE: RMD).
Mizuho Securities Analyst forecast on RMD
Anthony PetroneMizuho Securities
Mizuho Securities
$265$250
Buy
1.19%
Upside
Reiterated
04/24/25
ResMed price target lowered to $250 from $265 at MizuhoResMed price target lowered to $250 from $265 at Mizuho
Stifel Nicolaus Analyst forecast on RMD
Jonathan BlockStifel Nicolaus
Stifel Nicolaus
$240
Hold
-2.85%
Downside
Reiterated
04/24/25
Stifel Nicolaus Keeps Their Hold Rating on Resmed (RMD)
J.P. Morgan Analyst forecast on RMD
David LowJ.P. Morgan
J.P. Morgan
$286$290
Buy
17.39%
Upside
Reiterated
04/24/25
ResMed (RMD) PT Raised to $290 at JPMorganJPMorgan analyst David Low raised the price target on ResMed (NYSE: RMD) to $290.00 (from $286.00) while maintaining a Overweight rating.
William Blair Analyst forecast on RMD
Margaret KaczorWilliam Blair
William Blair
Buy
Reiterated
04/24/25
ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating
KeyBanc
Buy
Reiterated
04/24/25
KeyBanc Sticks to Their Buy Rating for Resmed (RMD)
Robert W. Baird Analyst forecast on RMD
Joseph VruwinkRobert W. Baird
Robert W. Baird
$286$252
Buy
2.00%
Upside
Reiterated
04/10/25
ResMed (RMD) PT Lowered to $252 at BairdBaird analyst Joe Vruwink lowered the price target on ResMed (NYSE: RMD) to $252.00 (from $286.00) while maintaining a Outperform rating.
Citi Analyst forecast on RMD
Unknown AnalystCiti
Not Ranked
Citi
Buy
Upgraded
03/05/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on RMD
David BaileyMorgan Stanley
Morgan Stanley
$280$286
Buy
15.77%
Upside
Reiterated
05/20/25
Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities
Bank of America Securities Analyst forecast on RMD
Lyanne HarrisonBank of America Securities
Bank of America Securities
$280
Buy
13.34%
Upside
Reiterated
05/20/25
Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109's Appeal
UBS
$285
Buy
15.36%
Upside
Reiterated
05/20/25
UBS reiterates Buy Rating on ResMed (RMD)UBS analyst Marcus Curley reiterated a Buy rating and $285.00 price target on ResMed (NYSE: RMD).
Needham
Hold
Reiterated
05/20/25
Resmed (RMD) Receives a Hold from Needham
Jefferies Analyst forecast on RMD
Unknown AnalystJefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on RMD.
RBC Capital Analyst forecast on RMD
Craig Wong-PanRBC Capital
RBC Capital
$247$255
Hold
3.22%
Upside
Reiterated
04/25/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), Resmed (NYSE: RMD) and Thermo Fisher (NYSE: TMO)
Piper Sandler Analyst forecast on RMD
Adam MaederPiper Sandler
Piper Sandler
$260$248
Hold
0.38%
Upside
Reiterated
04/24/25
Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)
Oppenheimer Analyst forecast on RMD
Suraj KaliaOppenheimer
Oppenheimer
Hold
Reiterated
04/24/25
Oppenheimer reiterates Perform Rating on ResMed (RMD)Oppenheimer analyst Suraj Kalia reiterated a Perform rating on ResMed (NYSE: RMD).
Mizuho Securities Analyst forecast on RMD
Anthony PetroneMizuho Securities
Mizuho Securities
$265$250
Buy
1.19%
Upside
Reiterated
04/24/25
ResMed price target lowered to $250 from $265 at MizuhoResMed price target lowered to $250 from $265 at Mizuho
Stifel Nicolaus Analyst forecast on RMD
Jonathan BlockStifel Nicolaus
Stifel Nicolaus
$240
Hold
-2.85%
Downside
Reiterated
04/24/25
Stifel Nicolaus Keeps Their Hold Rating on Resmed (RMD)
J.P. Morgan Analyst forecast on RMD
David LowJ.P. Morgan
J.P. Morgan
$286$290
Buy
17.39%
Upside
Reiterated
04/24/25
ResMed (RMD) PT Raised to $290 at JPMorganJPMorgan analyst David Low raised the price target on ResMed (NYSE: RMD) to $290.00 (from $286.00) while maintaining a Overweight rating.
William Blair Analyst forecast on RMD
Margaret KaczorWilliam Blair
William Blair
Buy
Reiterated
04/24/25
ResMed: Strong Financial Performance and Strategic Positioning Justify Buy Rating
KeyBanc
Buy
Reiterated
04/24/25
KeyBanc Sticks to Their Buy Rating for Resmed (RMD)
Robert W. Baird Analyst forecast on RMD
Joseph VruwinkRobert W. Baird
Robert W. Baird
$286$252
Buy
2.00%
Upside
Reiterated
04/10/25
ResMed (RMD) PT Lowered to $252 at BairdBaird analyst Joe Vruwink lowered the price target on ResMed (NYSE: RMD) to $252.00 (from $286.00) while maintaining a Outperform rating.
Citi Analyst forecast on RMD
Unknown AnalystCiti
Not Ranked
Citi
Buy
Upgraded
03/05/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

1 Month
xxx
Success Rate
12/19 ratings generated profit
63%
Average Return
+4.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +4.12% per trade.
3 Months
xxx
Success Rate
13/22 ratings generated profit
59%
Average Return
+5.00%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +5.00% per trade.
1 Year
David LowJ.P. Morgan
Success Rate
15/21 ratings generated profit
71%
Average Return
+5.26%
reiterated a buy rating last month
Copying David Low's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +5.26% per trade.
2 Years
xxx
Success Rate
18/22 ratings generated profit
82%
Average Return
+19.97%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +19.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
11
9
11
22
18
Hold
8
8
9
13
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
17
20
35
26
In the current month, RMD has received 18 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 265.11.
Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.48 with a range of $2.35 to $2.60. The previous quarter’s EPS was $2.37. RMD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s earnings estimate for RMD is $2.48 with a range of $2.35 to $2.60. The previous quarter’s EPS was $2.37. RMD beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.33B with a range of $1.30B to $1.35B. The previous quarter’s sales results were $1.29B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s sales forecast for RMD is $1.33B with a range of $1.30B to $1.35B. The previous quarter’s sales results were $1.29B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.34% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is 265.11.
    What is RMD’s upside potential, based on the analysts’ average price target?
    Resmed has 7.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RMD a Buy, Sell or Hold?
          Resmed has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Resmed’s price target?
            The average price target for Resmed is 265.11. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $290.00 ,the lowest forecast is $240.00. The average price target represents 7.31% Increase from the current price of $247.05.
              What do analysts say about Resmed?
              Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of RMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis